The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors. Tadalafi l (Cialis ® ; Eli Lilly and Company, Indianapolis, IN, USA) is the newest and most versatile PDE5 inhibitor in the clinical armamentarium for the treatment of ED. Its most unique characteristic is its long half-life of 17.5 hours, which lends itself to a longer therapeutic window with on-demand dosing and effective steadystate plasma concentrations with once-daily dosing. Clinical trials have proven its safety and effi cacy with both dosing strategies for all severities and etiologies of ED, including diffi cultto-treat ED. This thorough review will discuss ED, the physiology of penile erection and the role of PDE5, and all aspects of tadalafi l, from its development, through its pharmacology, to its latest clinical studies and indications.
Introduction
Attempts at determining the neurotransmitter or neurotransmitters involved in creating an erection may some day lead to successful nonhormonal medical therapy [for erectile dysfunction] (Krane 1986, p. 731 ).
-Robert J Krane, MD, in Campbell's Urology, Fifth Edition
The last two decades have seen a dramatic growth of understanding in the physiology of erection, the pathophysiology of erectile dysfunction (ED), and its treatment options. As the above quote from the fi fth edition of Campbell's Urology reveals, it was not long ago when little was known of erectile physiology, and adequate treatment was still "some day" away. Prior to the turn of the century, the pharmacologic treatment options for ED were cumbersome and invasive, limited to intracavernosal injections or intraurethral pellets. Everything changed when oral phosphodiesterase type 5 (PDE5) inhibitors became available, completely revolutionizing the treatment of ED of all severities and etiologies. Pfi zer introduced the fi rst PDE5 inhibitor, sildenafi l (Viagra ® ; Pfi zer, New York, NY, USA), in March of 1998, and over the past 10 years, the new oral pharmacologic therapy together with an unbridled acceptance and newfound candor by the general public has not only dramatically increased the awareness and prevalence of ED, but also made treatment of the disease simple and effective. Once one of the most frustrating and refractory diseases for the urologic specialist, ED is now enthusiastically discussed and treated in the primary care setting.
The addition of two more PDE5 inhibitors to the market in 2003 broadened the landscape of ED treatment and solidifi ed PDE5 inhibitors as safe and effective fi rst-line treatments for ED. With the development of the new PDE5 inhibitors, attention was focused on increased potency as well as duration of action. Tadalafi l (Cialis ® ; Eli Lilly and Company, Indianapolis, IN, USA), the newest of the three available PDE5 inhibitors, is similar to sildenafi l and vardenafi l (Levitra ® ; Bayer AG, Germany) in its mechanism of action, but differs primarily in its longer duration of action. In January 2008, Eli Lilly announced the latest innovation in the treatment of ED, Federal Drug Administration (FDA) approval for tadalafi l once-daily dosing in the treatment of ED.
In this review, we will highlight ED, the physiology of penile erection, and the role of PDE5 before focusing on the newest and most versatile PDE5 inhibitor. We intend to thoroughly report tadalafi l's pharmacology, safety, and drug interactions; its effi cacy, indications, and clinical trials; and its favorability by patients and partners. The reasons why tadalafi l is a distinct, effi cacious, and favorable treatment in the clinical armamentarium for the treatment of ED will be clear at the conclusion of this review.
Erectile dysfunction
ED is the inability to achieve and maintain an erection suffi cient to permit satisfactory sexual intercourse (NIH 1993) . Affecting 150 million men worldwide, ED is growing rapidly, and its prevalence is expected to double to greater than 300 million men worldwide over the next 20 years (McKinlay 2000) . According to data extrapolated from the Massachusetts Male Aging Study, the incidence of ED is increasing at an astronomical rate, with an expected incidence of over 600,000 new cases per year in white men aged 40 to 69 alone (Johannes et al 2000) . Despite its growing incidence, which is partly a result of the sexual awakening stimulated by the new pharmacologic therapies, ED remains underdiagnosed, with millions of men worldwide never coming to medical attention because of the sensitivity of the issue.
The pathophysiology of ED has a variety of etiologies including psychological, hormonal, neurogenic, vasculogenic, drug-induced, or cavernosal impairment from any of the aforementioned factors (Lue 2000) . The etiologies are frequently categorized into psychogenic, organic (hormonal, neurogenic, vasculogenic, drug-induced, and cavernosal impairment) , or the most common type of ED which is a mixed psychogenic and organic type (Lue 2000) .
The pharmacologic evolution that has occurred over the past several decades has directed the current understanding of the pathophysiology of the disease process. Until the 1980s, the treatment options were limited to psychosexual therapy and placement of penile implants, and through that time it was believed that ED was primarily due to psychogenic causes. With the introduction of prostaglandin intracavernosal injections in the late 1980s, the vasculogenic etiologies of ED became better understood, and the connection between late onset hypogonadism and ED led to research elucidating the hormonal etiologies of the condition (Kaminetsky 2008) . Finally, the new oral treatment with PDE5 inhibitors has led to the current understanding of the pathophysiology of ED as well as the physiology of erection.
The physiology of erection and the role of phosphodiesterase type 5
A penile erection is a transformation of erectile tissue and vasculature from a state of minimally-perfused fl accidity into an engorged state. It is mediated by a multifaceted succession of neural and vascular components, coupled with hormonal and psychological factors. Through complex neural pathways consisting of somatic sensory afferent (pudendal) and autonomic (cavernous) nerves, as well as supraspinal structures including the medial preoptic area and paraventricular nucleus of the hypothalamus, sexual arousal stimulates the release of neurotransmitters that initiate erection (Carson and Lue 2005) .
The primary erectile-mediating neurotransmitter is nitric oxide (NO), a short-lived, gaseous mediator. NO is synthesized in nonadrenergic, noncholinergic fashion by neuronal nitric oxide synthase (nNOS) in the cavernous nerves to initiate erection and by endothelial nitric oxide synthase (eNOS) in the endothelium to maintain erection during sexual stimulation (Hurt et al 2002) . NO passively crosses the cell membrane and activates soluble guanylyl cyclase (sGC) upon entering smooth muscle cytoplasm, which in turn increases the production of cyclic guanosine monophosphate (cGMP) by converting it from guanosine triphosphate (GTP) (Lincoln and Cornwell 1991) . The increased concentration of cGMP activates protein kinase G, also called cGMP-dependent kinase, which through phosphorylation of ion channels opens potassium channels and inhibits calcium channels. The resultant decrease in cytosolic calcium concentration favors smooth muscle relaxation (Dean and Lue 2005) .
The vascular smooth muscle relaxation simultaneously vasodilates arterioles and trabecular smooth muscle sinusoids within erectile tissue to increase penile blood fl ow. Subsequently, compression of the subtunical venules against the tunica albuginea occludes venous outfl ow. During the fi nal phase of rigid erection, robust contraction of the ischiocavernous muscles constricts the base of the blood-fi lled corpora cavernosa, causing the penis to become even harder. Arterial infl ow and venous outfl ow are temporarily occluded during this phase, and the intracavernous pressure can approach several hundred millimeters of mercury (Lue 2000) .
Detumescence results from sympathetic discharge with ejaculation, as well as at the molecular level with the cessation of NO release from the endothelium and the Tadalafi l and erectile dysfunction breakdown of cGMP and other secondary messengers by various phosphodiesterase (PDE) enzymes (Lue 2000) . PDE is an enzyme that 50 years ago was discovered to block the activity of the second messenger cyclic adenosine 3',5'-monophosphate (cAMP) in animal models (Sutherland and Rall 1958) . The PDE superfamily includes 11 families, PDE1 to PDE11, on 21 unique genes (Lin et al 2003) . They are distributed throughout various tissues, primarily in vascular, visceral, and pulmonary smooth muscle, and they regulate physiologic functions in multiple organ systems (Carson and Lue 2005) . In the penis, PDE acts to breakdown cGMP. Despite the observation that every family of PDE except PDE6 has been found in the corpus cavernosum, PDE5 is the most abundant PDE family in the penis (Carson 2007) . By inhibiting the breakdown of cGMP, PDE5 inhibitors create increased bioavailability of cGMP, which both facilitates and potentiates the NO-mediated relaxation of erectile smooth muscle with sexual stimulation.
Caffeine and theophylline were two of the fi rst drugs found to inhibit the PDE enzyme decades ago (Butcher and Sutherland 1962) . Over the past 30 years, inhibitors of several families of PDE have been developed to treat a number of diseases. These include the PDE3 inhibitors milrinone and amrinone developed in the 1980s for heart failure, a PDE4 inhibitor cilostazol developed for claudication, and the anti-platelet drug dipyridamole that inhibits PDE8, PDE9, and PDE5 (Carson and Lue 2005) . Papaverine was the fi rst PDE inhibitor used in the treatment of ED, and it is still used in practice today. Administered as an intracorporal injection, papaverine is a non-selective inhibitor of PDE3 and its isoforms (Carson 2007) . Originally investigated as a treatment for angina pectoris, the fi rst oral PDE5 inhibitor, sildenafi l, was fortuitously discovered to produce erections in study participants. It was later released in 1998 as the fi rst oral treatment for ED, and this was followed in 2003 by the release of two more PDE5 inhibitors, vardenafi l and tadalafi l.
History of the development of tadalafi l
The Bothell, Washington-based pharmacologic research company ICOS Corporation was started in 1990, and it began the initial cardiovascular testing of a PDE5 inhibitor called IC351 in 1993. Meanwhile, sildenafi l citrate (sildenafi l) was discovered to cause improved erectile function as a side effect in a trial testing its effi cacy for the treatment of angina pectoris in 1994. IC351 was patented that year, and phase I clinical trials began in 1995. Two years later, phase II clinical trials began on patients with ED.
The same year that the FDA approved sildenafi l as the fi rst PDE5 inhibitor for the treatment of ED, Eli Lilly and Company joined the ICOS Corporation to form Lilly ICOS LLC in 1998 to expand the marketing venture of the newest PDE5 inhibitor. Tadalafi l was offi cially born in the year 2000 when a new drug application was put forth for IC351 with the generic name tadalafi l and trade name Cialis.
In May 2002, the fi rst reports regarding the effi cacy and duration of action of tadalafi l for ED were presented at the 97th Annual Meeting of the American Urological Association (AUA) in Orlando, Florida, USA. Brock and colleagues presented their initial data supporting the effi cacy and safety of tadalafi l (Brock et al 2002b) , and Porst and colleagues presented that tadalafi l is effi cacious for up to 36 hours (Porst et al 2002) . Brock's data were published later that year in a landmark integrative analysis of fi ve randomized controlled trials of tadalafi l that ultimately led to the approval of the drug (Brock et al 2002a 
Tadalafi l pharmacology
The three available PDE5 inhibitors share a similar mechanism of action, but they have structural, pharmacologic, and clinical differences. The molecular structure of tadalafi l is available in Figure 1 . Tadalafi l's molecular structure is different than the similar structures of sildenafi l and vardenafi l. All three have a heterocyclic nitrogen-containing doublering system, with a central ring that is analogous to that of cGMP and allows for competitive binding of the drug with PDE5 at the catalytic site (Francis et al 2001) . Tadalafi l is different in that it is a β-carboline-type PDE5 inhibitor with a piperazinedione ring formed from a modifi cation of the hydantoin ring of sildenafi l (Francis et al 2001) .
Phosphodiesterase selectivity
Tadalafi l is at least 9000 times more selective for PDE5 than most of the other families of PDEs, with the exception of PDE11 (Briganti et al 2005) . PDE11 is found in the testes and prostate; however, despite partial inhibition of PDE11 by tadalafi l at therapeutic doses, clinical signifi cance of this observation has yet to be fully understood (ICOS 2008) . A study by Hellstrom and colleagues concluded that there are no harmful effects of tadalafi l on spermatogenesis or testicular function (Hellstrom et al 2003) .
The PDE enzyme responsible for phototransduction in the retina, PDE6, is inhibited to some degree by sildenafi l and vardenafi l, but not tadalafi l. The inhibition of PDE6 explains the side effect of blue vision experienced by some patients with these two drugs, as PDE6 inhibition in the retina causes impairment of blue-green color discrimination (Carson 2007) . Slightly less common with vardenafi l, altered vision is a reported side effect for 11% of men taking sildenafi l 100 mg (Montorsi et al 1999) . Compared with sildenafi l and vardenafi l, tadalafi l is much less inhibitory for PDE6, and it is over 700 times more potent for PDE5 than PDE6 (ICOS 2008) . For this reason, tadalafi l has less than 0.1% occurrence of vision abnormalities (Brock et al 2002; Carson et al 2004a) .
Dosing and absorption
Recommended starting doses of tadalafi l are 10 mg for on-demand dosing and 2.5 mg for once-daily dosing, and these doses can then be titrated up or down according to the effi cacy and tolerability (ICOS 2008) . It is absorbed as a low-solubility and high-permeability, or Class 2, drug within the FDA Biopharmaceuticals Classifi cation System (Gupta et al 2005) . With oral ingestion, after fi rst-pass metabolism, tadalafi l is approximately 80% bioavailable, compared to 40% and 15% with sildenafi l and vardenafi l, respectively (Francis and Corbin 2003) . Tadalafi l has the slowest absorption of the available PDE5 inhibitors with a mean of 2 hours to reach its maximum concentration, compared with about 50 minutes for sildenafi l and vardenafi l (Briganti et al 2005) . The onset of action of tadalafi l may occur in as early as 15 minutes of dosing, although successful erections occur in fewer than 40% of men at this time point (Brock et al 2002; Porst et al 2003) . It is not advisable to counsel patients that the drug effect may be seen in as early as 15 minutes because it may take up to 2 hours for a response in the majority of men. This may only create performance anxiety or loss of confi dence in the treatment, leading to treatment failure (Carson 2007) .
Differences in gastrointestinal absorption with fatty meals explain the varying peak plasma concentration (T max ) among the three PDE5 inhibitors (Corbin and Francis 2002) . While sildenafi l and vardenafi l both have decreased absorption when taken with a fatty meal, which may increase the rate of treatment failure, the absorption of tadalafi l is unaffected by fatty meals or alcohol consumption (Francis and Corbin 2003) . This unique pharmacokinetic trait for tadalafi l is a result of slower absorption and longer half-life, and it can therefore be taken with meals or alcohol without a decrease in effi cacy (Carson 2007 ).
Duration of action
Among the three PDE5 inhibitors, the half-life and thus duration of action is the pharmacologic parameter that is the most strikingly dissimilar. The half-life of tadalafi l is 17.5 hours in normal healthy men and 21.6 hours in elderly men, while the half-lives of sildenafi l and vardenafi l are similar at 4 hours (Francis and Corbin 2003) . This longer half-life provides a therapeutic window of 36 hours for tadalafi l (Porst et al 2003) .
The risks of a longer half-life have yet to be completely elucidated, but there does not appear to be any higher mortality with tadalafi l compared to the other PDE5 inhibitors. One difference resulting from the half-life disparity is that emergent treatment with nitrate medications must be deferred for at least 48 hours after ingestion of tadalafi l, compared with 24 hours for sildenafi l and vardenafi l (Kloner et al 2003a) .
Pharmacologic treatments for ED prior to tadalafil, including prostaglandin intracavernosal injections or intraurethral pellets, as well as the other two PDE5 inhibitors, all have a short half-life. For this reason, historically it has been necessary for ED treatments to be dosed immediately prior to attempting intercourse. A drawback to this necessary dosing schedule for short half-life ED treatments is potential performance anxiety. The therapeutic window of 36 hours of tadalafi l allows the patient more freedom to choose the timing and setting of the sexual encounter with his partner.
Other benefi ts of tadalafi l's longer half-life are still being explored. The 
Metabolism and excretion
The metabolism of tadalafil is via the hepatic enzyme cytochrome P450 34A (CYP34A) to a catechol metabolite, which undergoes further metabolism to its primary circulating metabolite, methylcatechol glucuronide, a 10,000-fold less potent molecule than tadalafi l (Gupta et al 2005) . The CYP34A metabolism pathway of tadalafil was verified with studies using a CYP34A inhibitor ketoconazole and a CYP34A inducer rifampin (Kostis et al 2005) . Tadalafi l is excreted largely as metabolites, approximately two-thirds into the feces and one-third into the urine (ICOS 2008).
Adverse events
A large study of 2102 men from 11 different multicentered, randomized, double-blind, placebo controlled trials of tadalafi l reported the drug is well tolerated overall (Carson et al 2004a) . Fifty-one percent of men using tadalafi l 20 mg had at least one adverse event (AE), but only 3.2% discontinued treatment. The most common AEs reported with the 20 mg dose were headache (15%), dyspepsia (8%), and back pain (5%) ( Table 1) (Carson et al 2004a) . Most AEs are a result of vasodilation of vascular beds other than in the penis.
Although frequently asked about by patients, priapism is rarely associated with PDE5 inhibitors. Several case reports have found an extraordinarily uncommon link between sildenafi l and priapism, and only a single case report exists in the literature implicating tadalafi l with priapism (King et al 2005) . PDE5 inhibitors including tadalafi l may actually have some benefi t in preventing recurrent, or stuttering, priapism. A small series of 4 men with stuttering priapism were administered daily PDE5 inhibitors, one case of which used tadalafi l, and all four men had decreases in priapism recurrences (Burnett et al 2006) .
Safety and drug interactions
As with every PDE5 inhibitor, tadalafil is absolutely contraindicated with nitrate medications for angina pectoris secondary to the potentiated hypotensive effect the drugs can have together. Because of the longer half-life, treatment with nitrate medications must be deferred for at least 48 hours after ingestion of tadalafi l, compared with 24 hours for sildenafi l and vardenafi l (Kloner et al 2003a) .
The cardiac effects of PDE5 inhibitors have received considerable attention because the drugs were originally studied as a treatment for angina pectoris secondary to their action of smooth muscle relaxation. All of the PDE5 inhibitor trials have tediously monitored study participants' vital signs, particularly heart rate and blood pressure, monitored drug effects on cardiac electrophysiology, and tabulated the numbers of cardiovascular adverse events (Carson 2005) .
In a review of more than 4000 patients from over 60 studies, data reported by Kloner and co-workers contended that tadalafi l does cause small changes in blood pressure secondary to its vasodilatory properties, but that the changes were not clinically meaningful (Kloner et al 2003b) . In a separate, more recent study, the same author retrospectively reviewed serious cardiovascular treatment-emergent adverse events reported in 36 tadalafi l trials and found that the incidence of these events were comparable among patients taking tadalafi l as needed, 3 times per week, once-daily, and placebo (Kloner et al 2006) . The Second Princeton Consensus Conference, an expert conference on sexual dysfunction and cardiac risk, convened in 2004 to develop practice guidelines for the management of ED in patients with signifi cant cardiac risk. After reviewing all available literature, the Second Princeton Consensus Conference not only determined that patients with signifi cant cardiac risk factors did not exhibit worsening ischemia or unstable hemodynamics while taking PDE5 inhibitors, but also that cardiovascular function was actually improved by PDE5 inhibitors in some studies (Kostis et al 2005) . Although reported with vardenafi l, prolongation of the QT c interval is not observed with tadalafi l (Kloner 2004 ).
Tadalafil does not cause increased hypotension or orthostatic hypotension in men that are also taking multiple antihypertensive medications, and it is safe and well tolerated in this population (Kloner et al 2003c) . The primary exception is with α-blockers. Frequently prescribed for men with benign prostatic hyperplasia (BPH) as well as for men with hypertension, α-blockers share a similar mechanism of action with PDE5 inhibitors through peripheral vasodilation and may have more of an additive effect than other antihypertensives. Recently, the FDA changed its previous recommendation from contraindicated co-administration to precautionary co-administration (Kostis et al 2005) . In a study of the blood pressure effects of tadalafi l coupled with either of two α-blockers, doxazosin (Cardura ® ; Pfi zer, New York, NY, USA) and tamsulosin (Flomax ® ; Boehringer Ingelheim, Ridgefi eld, CT, USA), the hypotensive effect of doxazosin was exaggerated by almost 10 mmHg with tadalafi l while there was no change in blood pressure with tamsulosin and tadalafi l . The authors concluded tamsulosin to be a safe α-blocker to administer concurrently with tadalafi l . Until more studies are available, precaution is recommended with the co-administration of tadalafi l with any α-blocker, including mixed α-blockers such as labetalol and carvedilol (Kostis et al 2005; ICOS 2008) .
Because of its metabolism through the cytochrome P450 pathway, tadalafi l is susceptible to changes in serum concentration by other drugs that inhibit or promote its metabolism. Inhibitors of the CYP34A enzyme include ketoconazole, erythromycin, grapefruit juice, and protease inhibitors, and co-administration of these drugs with tadalafi l may increase serum concentrations of tadalafi l. On the contrary, co-administration with inducers of CYP34A including rifampin, carbamazepine, phenytoin, and phenobarbital, would require a larger dose of tadalafi l for a similar clinical effect (Kostis et al 2005) .
Effi cacy
Tadalafi l is an effi cacious treatment for ED of all severities and etiologies. The largest data series exist for the general ED population with mild to moderate ED (Brock et al 2002a; Carson et al 2004a) , but tadalafi l has also been shown to be an effective treatment for diffi cult-to-treat ED such as more severe, organic ED evaluated in tertiary care centers (Carson et al 2005a) , ED secondary to diabetes mellitus (Saenz de Tejada et al 2002; Fonseca et al 2004) , and ED resulting from prostate cancer treatments such as prostatectomy (Montorsi et al 2004; Carson et al 2005b) and radiotherapy (Incrocci et al 2007) .
Several recent studies have shown a signifi cant treatment benefi t from once-daily, low-dose tadalafi 
Background on outcome measures
Although the effectiveness of PDE5 inhibitors on such intermediate objective outcomes as penile rigidity through penile plethysmography with the RigiScan device (Dacomed Corporation, Minneapolis, MN, USA) has been studied, measuring the therapeutic effectiveness of tadalafi l is more accurately defi ned through an integration of the patient's reported treatment response and tolerability with the reported satisfaction of both the patient and his partner (Carson et al 2004b) . Despite their intrinsically subjective nature, validated questionnaires are the preferred major outcome measure of treatment effectiveness of tadalafi l and other PDE5 inhibitors.
The International Index of Erectile Function (IIEF) was developed by Rosen and colleagues in 1997 as a multidimensional, 15-item, self-administered questionnaire with the goal of assessing fi ve domains of male sexual function including erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction (Rosen et al 1997) . The erectile function domain of the IIEF (IIEF-EF) contains 6 questions which the patient answers on a scale from 1 (never or almost never) to 5 (almost always or always), providing a total score of 6 to 30 points. The questions concern erectile frequency, fi rmness, penetration ability, maintenance frequency, maintenance ability, and erection confi dence (Rosen et al 1997) . Based on a controlled study of 1151 men taking sildenafi l in order to establish cutoff scores for the IIEF-EF, a score of 26 or greater is defi ned as normal function, mild ED is a score from 22 to 25, mild to moderate ED 17 to 21, moderate ED 11 to 16, and severe ED 6 to 10 (Cappelleri et al 1999) .
The Sexual Encounter Profi le (SEP) is a patient diary that has a series of questions that the patient answers after each sexual encounter. The second question in the SEP diary (SEP-Q2) is a measure of penetration, "Were you able to insert your penis into your partner's vagina?" The third question of the SEP (SEP-Q3) is a true measure of successful intercourse, "Did your erection last long enough for you to have successful intercourse?" In tadalafi l trials including data analyses of the SEP, the SEP-Q2 and SEP-Q3 are most often reported.
Less often but still occasionally reported in the literature is the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) score, which more reliably assesses the patient and his partner's satisfaction with ED treatments and explores the impact of patient and partner satisfaction on treatment continuation (Althof et al 1999) . Graded on a scale of 1 to 100, a score of 50 or higher indicates treatment satisfaction (Carson and Lue 2005) .
In addition to the IIEF and the SEP, many tadalafi l trials report a global overall assessment as provided by the patient, known as a Global Assessment Question (GAQ). It is a summary question to assess global improvement and to provide an indirect estimate of patient satisfaction. A frequently reported GAQ in tadalafi l trials is, "Did the treatment improve your erections?"
The general ED population
The most frequently referenced study supporting the effi cacy of tadalafi l is an integrated analysis of 5 randomized, doubleblind, placebo controlled, multicentered phase III trials from 1112 men at 74 centers worldwide (Brock et al 2002a) . The average age was 59, and the etiology of ED was 61% organic, 9% psychogenic, and 31% mixed. The ED severity at baseline was mild in 41%, moderate in 23%, and severe in 36%. Subjects were randomized to placebo or tadalafi l at doses from 2.5 mg to 20 mg and instructed to self-administer a dose before initiating intercourse up to once daily. IIEF-EF, SEP, and GAQ scores were assessed at baseline and at 12 weeks (Brock et al 2002a) .
Results of the integrated analysis found all doses of tadalafi l to enhance effi cacy outcomes (Brock et al 2002a) .
The IIEF-EF at the end of treatment increased by 6.5 in men receiving tadalafi l 10 mg and by 7.9 with the 20 mg dose, compared with 0.6 in men receiving placebo (p Ͻ 0.001). Successful intercourse attempts were increased in 34% of men with a 10 mg dose and 39% with a 20 mg dose versus a 6% improvement in the placebo group when the SEP-Q3 answers were compared after 12 weeks (p Ͻ 0.001). Tadalafi l remained effi cacious up to 36 hours, as more than 70% of attempts were successful from 30 minutes to 36 hours after dosing. On the GAQ, 81% of men reported improved erections overall with tadalafi l 20 mg compared with 35% in the placebo group (p Ͻ 0.001). The percentage of men receiving a 20 mg dose of tadalafi l who had complete resolution of ED as defi ned by an IIEF-EF of 26 or higher was 59%, compared with only 11% with placebo (Brock et al 2002a) .
In an update to Brock and colleagues' study, Carson and associates performed another integrated analysis on all available tadalafi l trials, including the original 1112 men in the 5 trials from Brock and colleagues' original study, plus an additional 1215 men from 6 more recently completed trials (Carson et al 2004a) . The same study design, safety measures, and statistical analysis were performed, except patients who received 2.5 mg and 5 mg doses in two of the earlier studies that were included in the analysis by Brock and colleagues were not included by Carson and associates. Only doses of 10 mg and 20 mg of tadalafi l were compared with placebo. The average age was 56, and the etiology of ED was 58% organic, 12% psychogenic, and 31% mixed. The ED severity at baseline was mild in 36%, moderate in 27%, and severe in 33%. Comorbidities included 29% of men with hypertension, 16% with hyperlipidemia, 20% with diabetes mellitus, and 5% with coronary artery disease (Carson et al 2004a) .
The results from the IIEF-EF, SEP-Q2, and SEP-Q3 are summarized in Figure 2 . There were robust mean improvements in the IIEF-EF score, with increases of 6.5 points with 10 mg of tadalafi l and 8.6 points with the 20 mg dose, versus only 0.9 points in the placebo group (p Ͻ 0.001) (Carson et al 2004a) . According to the SEP-Q3, successful intercourse attempts were improved by 34% to a total of 58% with 10 mg tadalafi l, and a 46% improvement to a total of 68% was seen with the 20 mg dose, compared with an 8% improvement to a 31% total with placebo (p Ͻ 0.001). When successful intercourse attempts with tadalafi l 20 mg were stratifi ed by time after dosing, tadalafi l remained almost equally effi cacious at 36 hours. At the endpoint of the trial using the GAQ, 71% and 84% of patients reported overall improved erections with the two doses of tadalafi l, respectively, compared with 33% with placebo (p Ͻ 0.001) (Carson et al 2004a) . This second integrated analysis of 11 tadalafi l trials concluded that tadalafi l is a very effective and well tolerated treatment for ED of all severities and etiologies in men of all ages in the general population.
Diffi cult-to-treat ED
In the two trials mentioned in the previous section, the patient population was largely a primary care population of relatively healthy men with ED of varying severities and etiologies. To the contrary, a multicentered, randomized, double-blind, placebo controlled trial evaluated how tadalafil 20 mg improved ED in men presenting to tertiary care centers with more severe, organic ED and with more comorbid medical conditions than previous studies (Carson et al 2005a) .
One hundred and ninety-fi ve men were allocated to receive tadalafi l 20 mg or placebo up to once daily for 12 weeks with simplifi ed dosing instructions (Carson et al 2005a) . Effi cacy was assessed using the IIEF-EF, the SEP, and a GAQ, and the EDITS was provided at the end of the trial to assess satisfaction of the patient and his partner. The mean baseline IIEF-EF was 13, with 33% of participants reporting mild ED, 23% with moderate ED, and 51% with severe ED at baseline. Organic ED predominated with 81%, followed by 3% of men with psychogenic ED, and 16% with mixed type. Comorbidities included 41% with hypertension, 36% with hyperlipidemia, 21% with diabetes mellitus, and 8% with coronary artery disease (Carson et al 2005a) .
Tadalafi l 20 mg improved the IIEF-EF by 6.9 compared with −0.2 in the placebo group (p Ͻ 0.001), improved successful intercourse attempts by 34% compared with 4.5% in the placebo group (p Ͻ 0.001), and 73% of patients in the tadalafi l group reported improved erections on the GAQ compared with 15% in the placebo group (p Ͻ 0.001). The overall EDITS score was 67 in the tadalafi l group compared with 36 in the placebo group (p Ͻ 0.001), and a signifi cant correlation was observed between the scores of the patient and his partner, demonstrating improved satisfaction with parallel improvement in partner satisfaction. This study concluded that even in a tertiary care population of patients with a higher incidence of severe, organic ED and comorbid medical conditions, tadalafi l remains a safe and well tolerated drug that signifi cantly improves ED treatment satisfaction for patients and partners (Carson et al 2005a) .
ED secondary to diabetes mellitus
ED is a common problem affl icting over a third of all men with diabetes mellitus type 2, and diabetes is independently responsible for a 3-to 4-fold increase in the risk of ED according to a survey of 1460 diabetic men (De Barardis et al 2003) . ED is strongly related to the severity of diabetes, with a higher incidence in patients with a long history of diabetes, patients using insulin, and patients with microvascular complications of diabetes (De Berardis et al 2003) . Diabetic men with ED also have signifi cantly worse disease-specifi c health-related quality of life (Penson et al 2003) .
In the largest original, prospective trial of tadalafi l in diabetic men, Sáenz de Tejada and co-workers reported that tadalafi l signifi cantly improves ED and is well tolerated in this population (Sáenz de Tejada et al 2002) . A total of 216 men with type 1 or type 2 diabetes mellitus were randomized to placebo, tadalafi l 10 mg, or tadalafi l 20 mg to be taken on-demand up to once daily for 12 weeks. The IIEF-EF, the SEP, and a GAQ were used to evaluate effi cacy. The average age was 56, and the duration of diabetes was 12 years on average. Ninety-one percent of men had type 2 diabetes while 9% had type 1 diabetes, 22% had microvascular complications, and over 81% of men had poorly controlled diabetes with a hemoglobin A 1c of greater than 7.0%. The baseline IIEF-EF was 12, corresponding to moderate severity ED (Sáenz de Tejada et al 2002) .
In diabetic men taking tadalafi l 10 mg or 20 mg, the IIEF-EF was improved by 6.4 and 7.3, respectively, compared with 0.1 with placebo (p Ͻ 0.001) (Sáenz de Tejada et al 2002) . Successful intercourse was improved by 28% and 29% in the two tadalafi l groups versus only 1.9% in the placebo group (p Ͻ 0.001). The GAQ revealed that only 25% of men in the placebo group felt they had improved erections, compared with 56% and 64% of men in the tadalafi l 10 mg and 20 mg groups, respectively (p Ͻ 0.001) (Sáenz de Tejada et al 2002) .
Results from a large, retrospective analysis of 12 randomized controlled trials of tadalafi l including over 600 diabetic men parallels the data reported by Sáenz de Tejada (Fonseca et al 2004) . The trials included in this retrospective analysis were many of the same trials analyzed in other integrated analyses reported here in this review. The average age was 57, and diabetic men had more severe ED than patients without diabetes at baseline with a mean IIEF-EF of 12.6 compared to 15 in patients without diabetes (p Ͻ 0.001). Comorbid conditions more common in the patients with diabetes included hypertension, hyperlipidemia, and coronary artery disease (Fonseca et al 2004) .
Diabetic men in the tadalafi l 10 mg and 20 mg groups had improvements of 6.2 and 7.4 in their IIEF-EF, respectively, versus 0.9 for placebo (p Ͻ 0.001) (Fonseca et al 2004) . Successful intercourse was improved by 30% and 37% in the tadalafi l 10 mg and 20 mg groups, respectively, compared with 4% in the placebo group (p Ͻ 0.001). Overall, erections were reported as improved in 75% for the 20 mg group, 61% for the 10 mg group, and 30% for the placebo group (Fonseca et al 2004) . According to these studies, ED secondary to diabetes is certainly amenable to treatment with tadalafi l.
ED after prostate cancer treatment
All of the available prostate cancer treatments, including radical prostatectomy, external beam radiation therapy, brachytherapy, cryotherapy, androgen-deprivation therapy, and even active surveillance alone, can result in ED. ED after prostate cancer treatment includes both organic and psychogenic causes, as signifi cant anxiety and depression may result from a diagnosis of prostate cancer, leading to psychogenic ED (Carson et al 2005b) .
The most important risk for organic ED after prostate cancer treatment of any type is damage to the cavernosal nerves. Walsh fi rst described the technique for sparing the bilateral neurovascular bundles to better preserve erectile function (Walsh et al 1983) , and a bilateral nerve sparing radical prostatectomy (BNSRP) is the surgical standard for prostate cancer today. Approximately 155,000 prostatectomies were performed in the United States in 2005 according to hospital discharge data (DeFrances 2007) . Potency in men after open BNSRP has a wide reported range of 10% to 97% in the literature (Talcott et al 1997; Stanford et al 2000; Walsh et al 2000; Menon et al 2005; Penson et al 2008) . Of 1288 men who underwent radical prostatectomy as part of the Prostate Cancer Outcomes Study, only 28% had erections suffi cient for intercourse at 5 years (Penson et al 2008) .
Cavernosal nerve injury during prostate cancer treatment is a neuropraxia resulting in atrophy of the cavernosal smooth muscle and abnormal deposition of collagen into the corpora cavernosa. Cavernosal hypoxia is another contributing factor in the development of fi brosis post-prostatectomy (Raina et al 2008) . The smooth muscle atrophy and fi brosis leads to corporal veno-occlusive dysfunction (CVOD), which is recognized as the primary cause of organic ED after prostate cancer treatment .
There are increasing experimental data that increased concentrations of NO and cGMP have an antifi brotic effect on tissues including the tunica albuginea and corporal tissue, supporting a role for tadalafi l to halt the pathophysiologic role of CVOD in post-prostate cancer treatment ED. Kovanecz and colleagues have recently studied the effect of once-daily tadalafi l on the prevention of fi brosis and CVOD after cavernosal nerve injury in rats (Kovanecz et al 2007) . Male rats had either a bilateral cavernosal nerve resection, unilateral cavernosal nerve resection, or a sham operation, and they were then either untreated or given once-daily tadalafi l. CVOD was assessed at 45 days with cavernosometry and histopathology. The authors found that tadalafi l normalized the increase in penile shaft collagen content, normalized the reduction in corporeal smooth muscle content, and improved the lower collagen type III:I ratio, effectively preventing CVOD and underlying corporal fi brosis after cavernosal nerve damage . Similarly, Vignozzi et al also found that once-daily tadalafi l given to rats that have undergone bilateral cavernosal nerve resection reversed the decline in cavernosal smooth muscle to collagen ratio (Vignozzi et al 2006) .
In the clinical arena, on-demand dosing of tadalafi l has been studied for ED secondary to BNSRP and external-beam radiotherapy (Incrocci et al 2006; Montorsi et al 2004) . Montorsi and associates evaluated on-demand dosing of tadalafi l 20 mg in men with ED following BNSRP in a randomized, double-blind, placebo controlled, multicentered study of 303 men over 12 weeks (Montorsi et al 2004) . All men had normal erectile function preoperatively and had undergone a BNSRP 12 to 48 months prior to the study. Primary endpoints were IIEF-EF, SEP-Q2, and SEP-Q3, and secondary endpoints were the GAQ and the EDITS questionnaire. Average age was 60 years, and 93% were white men. Almost two-thirds of the participants had some degree of postoperative tumescence at baseline as defi ned by reporting the ability "to achieve at least some erection" in over half of their sexual encounters on the SEP-Q1 (Montorsi et al 2004) . Among all patients, 62% responded to tadalafi l on the GAQ compared with 23% placebo (p Ͻ 0.001). Of those with some postoperative potency, 71% responded to tadalafi l compared with 24% placebo (p Ͻ 0.001). The SEP-Q3 revealed 41% of the total group had successful intercourse compared with 19% with placebo (p Ͻ 0.001). Over 50% of men with residual function had successful intercourse compared with 26% placebo (p Ͻ 0.001) (Montorsi et al 2004) . In this trial, tadalafi l was successful in producing erections suffi cient for intercourse in men with ED after BNSRP, but it was more effi cacious in men with some residual potency after surgery prior to treatment.
Sixty patients with ED after external-beam radiotherapy for prostate cancer were randomized to on-demand tadalafi l 20 mg or placebo in a double-blind, placebo controlled, crossover study lasting 12 weeks (Incrocci et al 2006) . Effi cacy was assessed with the IIEF-EF, SEP, and a GAQ. Average age was higher than most other tadalafi l studies at 69 years, the participants' prostate cancer tumor stages were 37% T1c, 37% T2, and 26% T3, and the baseline mean IIEF-EF score among all men revealed severe ED at 8.4. The IIEF-EF score improved to 17.7 with tadalafi l and to 9.5 with placebo (p Ͻ 0.0001). The SEP-Q3 data demonstrated 46% of participants successfully had intercourse with tadalafi l 20 mg compared with 12% with placebo (p Ͻ 0.0001), and 67% of patients taking tadalafi l 20 mg responded positively with the GAQ compared with 20% with placebo (p Ͻ 0.001) (Incrocci et al 2006) . This study was continued as an openlabel extension over 6 weeks. Fifty-one of 60 patients (85%) enrolled, who had a higher IIEF-EF score than those who did not enroll (p Ͻ 0.05). Tadalafi l was equally effective in the double-blind phase as in the open-label phase of the study (Incrocci et al 2007) .
Tadalafi l and other PDE5 inhibitors dosed both in continuous fashion and on-demand have been proposed for erectile rehabilitation and ED prophylaxis after BNSRP. In a small, prospective, observational study of 27 patients who underwent BNSRP, tadalafi l 20 mg was dosed every 3 days beginning on the fi rst postoperative day (Carson et al 2005b) . At 6 weeks, 89% of men reported erections, and 50% had successful intercourse. One-hundred percent had erections at 6 months, with 78% reporting successful intercourse (Carson et al 2005b) . Padma-Nathan and colleagues reported in a multicentered, placebo-controlled, prospective study of prophylactic sildenafi l dosed nightly beginning 4 weeks after BNSRP and continuing for 36 weeks that patients taking prophylactic sildenafi l had a 27% return of erectile function compared with only 4% in the placebo group (p Ͻ 0.05) (Padma-Nathan et al 2008) . A randomized, double-blind, multicentered study of early postoperative dosing with vardenafi l, dosed either once-daily or on-demand and compared with placebo, in 628 men after BNSRP found that on-demand vardenafi l treatment resulted in greater IIEF-EF scores and higher SEP-Q3 response rates than once-daily dosing or placebo (Montorsi et al 2008) . Although the effi cacy of postoperative treatment with PDE5 inhibitors to prevent CVOD and corporal fi brosis and reduce ED after BNSRP seems clear, it remains uncertain whether a continuous or an on-demand dosing strategy is superior in this setting.
Once-daily dosing
The latest innovation in the treatment of ED has arrived in the form of a simpler, once-daily dosing schedule for tadalafi l, unlinking the temporal association of the medication and the sexual encounter. The unnatural process of taking a medication just prior to sex is a negative aspect of ED treatment for many patients (Hanson-Divers et al 1998) . The 17.5 hour half-life of tadalafi l lends itself to daily dosing because steady-state plasma concentrations are attained within fi ve days of initiating daily dosing (Forgue et al 2006) . Additionally, at steady-state concentration, the daily exposure is 1.6-fold greater than the same dose taken intermittently (Forgue et al 2006) . Therefore, after 5 days of once-daily dosing, the plasma concentration of tadalafi l achieved with a 2.5 mg and 5 mg dose is 4 mg and 8 mg, respectively. The FDA announced approval for once-daily dosing of tadalafi l in January 2008 after a thorough review of the studies outlined below.
McMahon has compared once-daily with on-demand dosing of tadalafi l in two independent, open-label studies in Australian men with ED (McMahon 2004; McMahon 2005) . In 112 men with ED who were previously unresponsive to on-demand tadalafi l, once-daily tadalafi l at fl exible doses of 10 mg and 20 mg for 12 weeks was provided (McMahon 2004) . Baseline IIEF-EF, SEP, and GAQ data were obtained from the cohort prior to any treatment with tadalafi l and after the trial of on-demand tadalafi l. Changes in the scores from both baselines were assessed after 12 weeks of daily dosing. Patients taking tadalafi l 10 mg once-daily improved the IIEF-EF score 12.8 from the no-treatment baseline and 8.2 from the on-demand treatment baseline (p Ͻ 0.001). . While both dosing strategies were effi cacious, the once-daily dosing of tadalafi l improved the IIEF-EF score by 11.9, compared to an improvement of 8.3 with the on-demand dosing (p Ͻ 0.05). Additionally, compared with 30% at baseline, successful intercourse was reported in the SEP-Q3 in 69% and 84% of patients taking on-demand and once-daily tadalafi l, respectively (p Ͻ 0.05). Overall, once-daily dosing was preferred by 72% of the patients (McMahon 2005) .
The first multicentered, randomized, double-blind, placebo controlled study of once-daily tadalafi l enrolled 268 men over 12 weeks and compared tadalafi l 5 mg and 10 mg taken once-daily with placebo (Porst et al 2006) . The study took place in 20 centers across Europe and South America in men with ED of all severities and etiologies. IIEF-EF, SEP, and GAQ were assessed at baseline and at 12 weeks. The mean IIEF-EF change from baseline at the endpoint was 9.7 and 9.4 for tadalafi l 5 mg and tadalafi l 10 mg, respectively, compared with 0.9 for placebo (p Ͻ 0.001). Successful intercourse was achieved in 67.2% and 72.8%, compared with 36.7% with placebo (p Ͻ 0.001). The authors concluded once-daily tadalafi l 5 mg or 10 mg signifi cantly improved erectile function in men with ED (Porst et al 2006) .
Rajfer and associates performed a similar study of once-daily tadalafi l in American men with lower doses over a longer study duration (Rajfer et al 2007) . Once-daily tadalafi l 2.5 mg, 5 mg, or placebo was dosed over a 24 week period in a randomized, double-blind, placebo controlled, parallel-design study in 287 men evaluated in 15 US centers. Primary endpoints included the change from baseline to 24 weeks in mean IIEF-EF score and the percentage of "yes" responses in SEP-Q2 and SEP-Q3. The IIEF-EF and SEP data are summarized in Figure 3 . The IIEF-EF score had a mean improvement over 24 weeks of 6.0 and 7.0 in the tadalafi l 2.5 mg and 5 mg groups, respectively, compared with 1.2 in the placebo group (p Ͻ 0.001). Successful intercourse was improved over the 24-week period in 31.2% and 35.1% in the tadalafi l groups compared with 9.5% with placebo (p Ͻ 0.001) (Rajfer et al 2007) . In open-label extensions of the two randomized, placebo controlled trials of once-daily tadalafi l described above, Porst and colleagues have evaluated the long-term safety and effi cacy of once-daily tadalafi l 5 mg over 1 and 2 years (Porst et al 2008) . There were 208 of 234 possible patients (88.9%) who completed the 1-year extension and 139 of 238 possible patients (58.4%) who completed the 2-year extension. Efficacy was measured by changes in the IIEF-EF score, SEP, and the GAQ. The IIEF-EF score improved from baseline by 10.4 and 10.8 in the 1-and 2-year extensions, respectively. After 2 years, 95.7% of patients reported improved erections (Porst et al 2008) . Although an impressively positive response, the 2-year GAQ data had a signifi cant dropout rate and likely contained selection bias toward patients who had a positive response.
Once-daily tadalafil has recently been studied in a population of men with ED secondary to diabetes mellitus (Hatzichristou et al 2008) . A randomized, double-blind, placebo controlled, multicentered study in North America, Europe, and Australia enrolled 298 diabetic men with ED and randomized them to tadalafi l 2.5 mg, 5 mg, or placebo for 12 weeks. IIEF-EF, SEP, and GAQ were measured as primary outcomes. The mean age was 57, 42.6% of patients had severe ED, and comorbid conditions were prevalent and included 54% with hypertension and 43% with dyslipidemia. Eighty-nine percent of patients had diabetes mellitus type 2, average hemoglobin A 1c was 7.7%, and glycemic control was good in 39%, fair in 48%, and poor in 13%. Mean changes in IIEF-EF scores were modest, including 4.8 and 4.5 for the tadalafi l 2.5 mg and 5 mg groups, respectively, compared with 1.3 for placebo (p Ͻ 0.005). Successful intercourse was improved by 25.9% and 25% in the tadalafi l groups, versus 8.2% placebo (p Ͻ 0.005). In this fi rst study of once-daily tadalafi l in diabetic men with ED, 2.5 mg and 5 mg once-daily both produced modest improvements in erectile function in this population (Hatzichristou et al 2008) .
New applications
Recent data have indicated a potential association between epidemiological, physiologic, pathophysiologic, and treatment aspects of ED and lower urinary tract symptoms (LUTS) secondary to BPH (McVary and McKenna 2004) . The 17.5 hour half-life of tadalafi l makes it the most suitable PDE5 inhibitor for once-daily dosing in a trial of LUTS secondary to BPH. McVary and associates reported a multicentered, randomized, double-blind, placebo controlled study of 281 men with LUTS secondary to BPH who were randomly assigned to once-daily tadalafi l 5 mg for 6 weeks, followed by dose escalation to 20 mg for 6 weeks, or 12 weeks of placebo. They reported modest decreases in International Prostate Symptom Score (IPSS), with a mean change from baseline to 6 weeks of −2.8 with tadalafi l 5 mg versus −1.2 with placebo (p Ͻ 0.003), and to 12 weeks of −3.8 with tadalafi l 5/20 mg versus −1.7 with placebo (p Ͻ 0.001) (McVary et al 2007) .
To further examine the effi cacy and dose response of tadalafi l in men with LUTS secondary to BPH, Roehrborn and colleagues performed a similar multicentered, randomized, double-blind, placebo controlled study with a larger sample size and different tadalafi l doses (Roehrborn et al 2008) . The 1058 men with LUTS secondary to BPH in the study received once-daily placebo or tadalafi l (2.5, 5, 10 or 20 mg) for 12 weeks. The IPSS mean change from baseline to endpoint after 12 weeks was signifi cantly improved, -3.9 for tadalafi l 2.5 mg (p Ͻ 0.015), −4.9 for tadalafi l 5 mg (p Ͻ 0.001), −5.2 for tadalafi l 10 mg (p Ͻ 0.001), and −5.2 for tadalafi l 20 mg (p Ͻ 0.001), compared with −2.3 for placebo. The optimal risk-benefi t profi le for men with LUTS secondary to BPH was achieved with the tadalafi l 5 mg dose (Roehrborn et al 2008) .
These observations may be a result of increased cGMP causing a decrease in prostatic muscle tension (Uckert et al 2001) , NO effect on the smooth muscle of the bladder, PDE inhibition in the prostate and prostatic urethra, or some other process not yet defi ned. Further basic science and clinical research is necessary to defi ne the role of tadalafi l's effect on the bladder, the prostate, and LUTS.
Patient preference
There have been several crossover trials that have attempted to compare patient and partner preference between sildenafi l and tadalafi l. Comparing the PDE5 inhibitors is intrinsically diffi cult because of the differences in dosing, absorption, duration of action, and other pharmacologic parameters (Carson and Lue 2005) . Regardless, consensus results across multiple studies declare tadalafi l as preferred over sildenafi l by patients and their partners for the treatment of ED.
In a study to determine the proportion of current sildenafi l users that would switch to tadalafi l versus resume sildenafi l after given a trial with tadalafi l, 133 of 147 (90.5%) patients elected to switch to tadalafi l in the extension phase of the trial, irrespective of age group, severity of ED, or etiology of ED (Ströberg et al 2003) . Prospective, randomized studies including over 750 men with various severities and etiologies of ED have found a preference for tadalafi l over sildenafi l by signifi cant margins (Eardley et al 2005; Govier et al 2003; von Keitz et al 2004) . A randomized, crossover study of 215 men with ED found 66.3% preferred tadalafi l over sildenafi l for initiation of ED therapy (Govier et al 2003) . Another randomized, double-blind, crossover study comparing tadalafi l with sildenafi l reported that 132 of 181 (73%) chose to receive tadalafi l during the extension phase of the trial, irrespective of previous sildenafi l use (p Ͻ 0.001) (von Keitz et al 2004) . The results were even more disproportionate when stratifi ed by other comorbid diseases. Men with diabetes had an 87% preference for tadalafi l over sildenail (p Ͻ 0.001), and men with hypertension had a 79% preference for tadalafi l (p Ͻ 0.001) (von Keitz et al 2004) . The largest and most recent randomized, crossover, open-label study of sildenafi l and tadalafi l included 291 men naïve to PDE5 inhibitor therapy who were randomized to one drug for 12 weeks followed by the other for another 12 weeks, with a fi nal 8-week extension phase during which time the patients chose their preferred agent (Eardley et al 2005) . Effi cacy of the two drugs was measured by IIEF-EF scores and a SEP diary. After completing both treatments, 71% men chose tadalafi l in the extension phase compared to 29% sildenafi l (p Ͻ 0.001). The IIEF-EF and SEP-Q2 were not signifi cantly different, although the SEP-Q3 measuring successful intercourse was 77% with tadalafi l compared with 72% with sildenafi l (p Ͻ 0.003) (Eardley et al 2005) .
The Partner's Preference Study was a randomized, crossover study from a single center comparing tadalafi l and sildenafi l in 100 couples with the male partner having ED (Conaglen and Conaglen 2008) . The couples were randomly assigned to tadalafi l or sildenafi l for 12 weeks followed by a second phase with 12 weeks of the alternate drug. Men and their partners completed SEP diaries, and the primary outcome data were the female partners' fi nal interviews during which they provided their preference between the two drugs. Tadalafi l was preferred by the female partner in 79.2%, while 15.6% preferred sildenafi l. The number of events recorded, timing of the events, and the number of doses were not signifi cantly different between the groups. The female partners reported more relaxed, more satisfying, and longer-lasting sexual experiences with tadalafi l as compared with sildenafi l (Conaglen and Conaglen 2008) .
Conclusion
Tadalafi l is a safe, well tolerated, and effi cacious treatment for all severities and etiologies of ED. Its effi cacy has been proven in numerous clinical trials, and it is effective not only in the general ED population, but also the diffi cultto-treat ED population with more severe ED and a greater number of comorbidities. Its most unique characteristic is its long half-life of 17.5 hours, which lends itself to a longer therapeutic window with on-demand dosing and effective steady-state plasma concentrations with once-daily dosing. Taken on-demand or once-daily, tadalafil significantly enhances erectile function. Its newest indication for oncedaily dosing disconnects the temporal association of dosing a medication prior to the sexual encounter. These attributes make tadalafi l a distinct, effi cacious, and favorable treatment in the clinical armamentarium for the treatment of ED.
